Article: Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma.
Oncology (Williston Park, N.Y.)
2023 Volume 37, Issue 10, Page(s) 419–424
Abstract: Predominantly autoimmune in origin, severe normochromic, normocytic anemia with reticulocytopenia in the setting of the normal production of leukocytes and megakaryocytic lineages is known as pure red cell aplasia (PRCA), which is unlike aplastic anemia ... ...
| Abstract | Predominantly autoimmune in origin, severe normochromic, normocytic anemia with reticulocytopenia in the setting of the normal production of leukocytes and megakaryocytic lineages is known as pure red cell aplasia (PRCA), which is unlike aplastic anemia in which all lineages are affected due to a stem cell defect. PRCA can be primary (such as autoimmune) or acquired, which can be an acute self-limited illness or a chronic disease that may be induced by medications, including immunotherapy such as monoclonal antibodies (mAbs). Daratumumab is a mAb directed against CD38 used for the treatment of multiple myeloma and systemic amyloid light-chain amyloidosis. The intravenous formulation of daratumumab received initial FDA approval, and later approval was received for the subcutaneous formulation daratumumab and hyaluronidase-fihj. The subcutaneous version increases patient convenience and has become the preferred route of administration since its approval. We herein present the case of a patient with multiple myeloma who developed acquired DNMT3A-positive PRCA while transitioning to daratumumab/hyaluronidase after initial treatment with daratumumab. |
|---|---|
| MeSH term(s) | Humans ; Multiple Myeloma/drug therapy ; Hyaluronoglucosaminidase ; Red-Cell Aplasia, Pure/chemically induced ; Red-Cell Aplasia, Pure/drug therapy ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents |
| Chemical Substances | daratumumab (4Z63YK6E0E) ; Hyaluronoglucosaminidase (EC 3.2.1.35) ; Antibodies, Monoclonal ; Antineoplastic Agents |
| Language | English |
| Publishing date | 2023-10-25 |
| Publishing country | United States |
| Document type | Case Reports ; Journal Article |
| ZDB-ID | 1067950-9 |
| ISSN | 0890-9091 |
| ISSN | 0890-9091 |
| DOI | 10.46883/2023.25921006 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3168: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 372: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.